Chartwell Investment Partners, LLC Cyma Bay Therapeutics, Inc. Transaction History

Chartwell Investment Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	BUY	$12.63 - $24.47 $4,546 - $8,809	360 Added 0.73%	49,388 $1.17 Million
Q2 2023 Jul 25, 2023	BUY	$7.47 - $10.95 $17,726 - $25,984	2,373 Added 5.09%	49,028 $536,000
Q1 2023 Apr 14, 2023	BUY	$5.88 - $9.59 $274,331 - $447,421	46,655 New	46,655 $406,000
Q3 2018 Nov 08, 2018	SELL	$10.88 - $14.52 $1.06 Million - $1.42 Million	-97,770 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$10.66 - $14.38 $1.04 Million - $1.41 Million	97,770 New	97,770 $1.31 Million
Q1 2018 May 08, 2018	SELL	$9.0 - $15.16 $643,581 - $1.08 Million	-71,509 Closed	0 $0
Q1 2018 May 08, 2018	BUY	$9.0 - $15.16 $643,581 - $1.08 Million	71,509 New	71,509 $929,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Chartwell Investment Partners, LLC with notifications on news.